This project required multiple assessments. See how Citeline dug deep to uncover protocol constraints, develop country and site strategy, research competitive intensity, and identify real-world patient patterns.
key findings
89% Site validation
8 Priority countries
20% Enrollment uplift
FAQ
What problem was Biorasi trying to solve in this Phase III oncology trial?
The trial was struggling to secure sites, decline rates were high, and too few potentially eligible patients were making it through screening – prompting the need for a rescue plan.
What were the two hypotheses Citeline helped validate?
Citeline helped Biorasi assess whether (1) the sponsor was targeting the wrong sites, or (2) the protocol design was creating barriers for investigators and patients.
What outcomes did the analysis deliver?
The work confirmed the sponsor was generally on the right track with sites. Citeline identified 199 additional high-quality US sites and eight countries for potential expansion. Its analysis supported a protocol amendment projected to boost enrollment 15% to 20%.
This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.
